RJA
ZNTL icon

Raymond James & Associates’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Raymond James & Associates’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$58.4K Buy
15,865
+4,626
+41% +$16.8K ﹤0.01% 3836
2024
Q2 		$46K Sell
11,239
-874
-7% -$9.76K ﹤0.01% 3800
2024
Q1 		$191K Buy
+12,113
New +$167K ﹤0.01% 3629

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Raymond James & Associates's ZNTL Position: Q3 2024 in Review

Raymond James & Associates increased its Zentalis Pharmaceuticals (ZNTL) stake by 41% in Q3 2024, buying an estimated $16.8K and bringing the position to 15,865 shares worth $58.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3836.

Raymond James & Associates first reported a position in ZNTL in Q1 2024 and has held it in 3 quarters since. The position peaked at $191K in Q1 2024. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • Raymond James & Associates held 15,865 shares of Zentalis Pharmaceuticals worth $58.4K as of Q3 2024.
  • Raymond James & Associates bought 4,626 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $16.8K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3836 holding.
  • Raymond James & Associates first reported a position in Zentalis Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • Raymond James & Associates's Zentalis Pharmaceuticals position peaked at $191K in Q1 2024.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.